Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

NCT02968303 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Melanoma, Malignant, of Soft Parts

Interventions

DRUG: Vemurafenib and Cobimetinib

Sponsor

Radboud University Medical Center

Collaborators

[object Object]
[object Object]